Intensity Therapeutics, Inc.
INTSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 19, 2026 | H.C. Wainwright | Swayampakula Ramakanth | $7.00(+66%) | $4.21 | StreetInsider |
| Aug 11, 2026 | Industrial Alliance Securities | James Molloy | $15.00(+257%) | $4.20 | TheFly |
| Oct 31, 2024 | H.C. Wainwright | Swayampakula Ramakanth | $5.00(-93%) | $76.25 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| StoneX | maintain | Speculative Buy | Nov 6, 2026 |
| HC Wainwright & Co. | maintain | Buy | Aug 18, 2026 |
| Benchmark | maintain | Speculative Buy | Aug 20, 2025 |
| Brookline Capital | upgrade | Hold →Buy | Aug 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 21, 2024 |
| Benchmark | maintain | Speculative Buy | Jul 11, 2024 |
| Benchmark | maintain | Speculative Buy | May 16, 2024 |
| Benchmark | maintain | Speculative Buy | Mar 21, 2024 |
| Benchmark | maintain | Speculative Buy | Nov 14, 2023 |
| Benchmark | maintain | Speculative Buy | Aug 24, 2023 |
Earnings History
Next report: Mar 18, 2027 · EPS est. $-0.75| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $-1.09 | $-0.99 | — | — |
| Aug 11, 2026 | $-1.11 | $-0.87 | — | — |
| May 7, 2026 | $-0.96 | $-1.19 | — | — |
| Mar 27, 2026 | $-1.69 | $-1.24 | — | — |
| Nov 6, 2025 | $-1.50 | $-1.58 | — | — |
| Aug 7, 2025 | $-3.25 | $-0.30 | — | — |
| May 13, 2025 | $-5.50 | $-5.00 | — | — |
| Mar 13, 2025 | $-5.50 | $-5.60 | — | — |
News
Intensity Therapeutics, Inc. ( INTS ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Lewis Bender - Founder, President, CEO & Chairman of the Board Joseph Talamo - Chief Financial Officer Conference Call Participants Kumaraguru Raja - Brookline Capital Markets, LLC, Research Division Charles Wallace - H.C. Wainwright & Co, LLC, Research Division Ilya Zubkov - Freedom Broker, Research Division James Molloy - Alliance Global Partners, Research Division Conversation Operato…
New patient enrollment activities resumed in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study in the third quarter of 2026 New patient enrollment and treatment resumed in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study in the third quarter of 2026 Cash and cash equivalents of $8.5 million as of September 30, 2026 Conference call begins at 8:00 a.m. Eastern time today SHELTON, Conn.
Company to hold a conference call at 8AM ET on November 5, 2026 to review results and provide a corporate update SHELTON, Conn., Oct. 30, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology,…
Pathological complete response (pCR) achieved in the breast (ypT0/Tis) and affected lymph nodes (ypN0) in 5 out of 7 patients (71%; 95% CI 29-96%) in the INT230-6 plus standard-of-care cohort No invasive breast cancer cells were detected in the axillary lymph nodes in 6 of the 7 INT230-6 patients after INT230-6 treatment, despite 5 (71%) of the patients were initially biopsy-proven node-positive SHELTON, Conn., Oct. 23, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity…
SHELTON, Conn., Sept. 8, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces that it will participate in the H.C.
Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript
Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026 Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study Cash and cash equivalents of $9.5 million as of June 30, 2026 Increased business development activities Conference call begins at 8:00 a.m. Eastern time today SHELTON, Conn.